XRAY Stock Analysis — Dentsply Sirona
Sector: Healthcare
AI Verdict
XRAY trades at a rock-bottom multiple because the market doubts its ability to grow, and unless its dental franchise delivers a clear turnaround, the low price may be justified.
Competitive Moat
Dentsply Sirona manufactures dental equipment and consumables, benefiting from entrenched relationships with dental practices and a broad product portfolio that makes switching costly for clinics. Its global distribution network and integration of digital dental technologies create barriers for smaller competitors.
Summary
XRAY trades at a steep discount to healthcare peers, reflecting skepticism about its ability to reignite growth.
Where It Stands
With a forward P/E of 9.2x versus the healthcare sector median of 22x and trailing revenue down -0.8% year-over-year, the stock is priced for minimal growth and faces pressure to turn the business around.
Key Metrics
- Forward P/E: 9.2x
- Revenue Growth: -0.0%
- Dividend Yield: 0.05%
- 52-Week High: $14.76
- 52-Week Low: $9.41
Analyst Consensus
8 Buy · 13 Hold · 2 Sell (23 analysts)
Bull Case
At 9.2x next year's earnings, the stock is cheap for a company with a defensible dental equipment moat if it can stabilize sales.
Bear Case
With revenue shrinking -0.8% year-over-year, even a modest P/E re-rating to the sector median would require a dramatic turnaround that the recent numbers don't support.
Catalyst to Watch
Watch for quarterly earnings updates showing a return to revenue growth, as even modest improvement could trigger a re-rating from the current depressed multiple.